What is the prevalence of Choroideremia?

Choroideremia is a rare, X-linked recessive genetic disorder with an estimated prevalence ranging from 1 in 50,000 to 1 in 100,000 individuals. Because of its X-linked inheritance pattern, Choroideremia predominantly affects males, while female carriers typically remain asymptomatic or experience very mild symptoms.

What is the estimated prevalence and incidence of Choroideremia?

The prevalence of Choroideremia is estimated to be approximately 1 in 50,000 to 100,000 in the general population, though these figures are often considered conservative estimates due to potential underdiagnosis. Reliable incidence data (new cases per year) is difficult to establish because Choroideremia is frequently misdiagnosed as other forms of retinal degeneration, such as Retinitis Pigmentosa. Within the DiseaseMaps.org community, 96 people have joined to share their experiences with Choroideremia, providing a vital, real-world perspective on living with this rare condition that often goes uncounted in traditional clinical registries.

Who is most affected by Choroideremia?

Choroideremia is an X-linked condition, meaning it is caused by mutations in the CHM gene located on the X chromosome. Key demographic factors include:

• Gender: It primarily affects males. Females are typically carriers and usually do not develop the severe vision loss associated with the disease.


• Age of Onset: Night blindness often begins in early childhood (typically the first decade of life), followed by progressive peripheral vision loss in adolescence or early adulthood.


• Geography/Ethnicity: There is no evidence of specific geographic or ethnic clustering for Choroideremia; it is found globally across diverse populations.

Why is accurate data for Choroideremia difficult to obtain?

The rarity of Choroideremia presents significant epidemiological challenges. Because it is a progressive, inherited retinal dystrophy, patients may be misdiagnosed early in life. Furthermore, because it is an ultra-rare condition, many healthcare providers may not encounter a case during their entire practice, leading to a lack of awareness and delayed genetic testing. The 96 members of the DiseaseMaps.org community highlight the importance of patient-led data in filling these knowledge gaps.

Next steps

• Consult a retinal specialist or an ophthalmologist with expertise in inherited retinal diseases.


• Undergo genetic testing to confirm the CHM gene mutation.


• Connect with the 96 members on DiseaseMaps.org to share insights and support.


• Register with patient advocacy groups like the Choroideremia Research Foundation for clinical trial updates.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; always consult a qualified healthcare provider for diagnosis and treatment.

References

• Orphanet (ORPHA166): Choroideremia overview.


• NIH Genetic and Rare Diseases Information Center (GARD): Choroideremia statistics.


• OMIM (Online Mendelian Inheritance in Man): #303100 Choroideremia.


• Choroideremia Research Foundation: Patient resources and clinical data.